BioVie Secures $12.6 Million Grant for Phase 2 Trial of Bezisterim Targeting Long COVID
Understanding the Importance of Bezisterim in Long COVID Treatment
BioVie Inc. has announced a remarkable achievement with the approval of a $12.6 million grant from the U.S. Department of Defense. This funding is aimed at initiating a Phase 2 trial for its innovative drug, Bezisterim, specifically targeting long COVID symptoms.
The Significance of the Trial
- This trial marks a vital step in addressing the long-term health complications associated with COVID-19.
- Bezisterim's potential efficacy could lead to better management of persistent symptoms.
- The grant showcases support for medical research focusing on health after viral infections.
As the healthcare industry continues to recognize the implications of long COVID, studies like this are crucial for developing effective treatment strategies.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.